207 related articles for article (PubMed ID: 31526232)
1. Hit identification and drug repositioning of potential non-nucleoside reverse transcriptase inhibitors by structure-based approach using computational tools (part II).
Cutinho PF; Shankar RC; Anand A; Roy J; Mehta CH; Nayak UY; Murahari M
J Biomol Struct Dyn; 2020 Aug; 38(13):3772-3789. PubMed ID: 31526232
[TBL] [Abstract][Full Text] [Related]
2. Design of metronidazole derivatives and flavonoids as potential non-nucleoside reverse transcriptase inhibitors using combined ligand- and structure-based approaches.
Cutinho PF; Roy J; Anand A; Cheluvaraj R; Murahari M; Chimatapu HSV
J Biomol Struct Dyn; 2020 Apr; 38(6):1626-1648. PubMed ID: 31046644
[TBL] [Abstract][Full Text] [Related]
3. Application of Molecular Docking for the Development of Improved HIV-1 Reverse Transcriptase Inhibitors.
Soltani A; Hashemy SI; Avval FZ; Rafatpanah H; Rezaee SA; Griffith R; Mashkani B
Curr Comput Aided Drug Des; 2021; 17(4):538-549. PubMed ID: 32598265
[TBL] [Abstract][Full Text] [Related]
4. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
[TBL] [Abstract][Full Text] [Related]
5. New strategy for identifying potential natural HIV-1 non-nucleoside reverse transcriptase inhibitors against drug-resistance: an
Wang Y; Wang X; Xiong Y; Kaushik AC; Muhammad J; Khan A; Dai H; Wei DQ
J Biomol Struct Dyn; 2020 Jul; 38(11):3327-3341. PubMed ID: 31422767
[TBL] [Abstract][Full Text] [Related]
6. In silico design, synthesis and anti-HIV activity of quinoline derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Singh VK; Mishra R; Kumari P; Som A; Yadav AK; Ram NK; Kumar P; Schols D; Singh RK
Comput Biol Chem; 2022 Jun; 98():107675. PubMed ID: 35395595
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
Ghosn J; Chaix ML; Delaugerre C
AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship studies on clinically relevant HIV-1 NNRTIs.
Rawal RK; Murugesan V; Katti SB
Curr Med Chem; 2012; 19(31):5364-80. PubMed ID: 22998569
[TBL] [Abstract][Full Text] [Related]
9. Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1).
Xu H
Mini Rev Med Chem; 2010 Jan; 10(1):62-72. PubMed ID: 20380641
[TBL] [Abstract][Full Text] [Related]
10. [Non-nucleoside reverse transcriptase inhibitors].
Joly V; Yeni P
Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953
[TBL] [Abstract][Full Text] [Related]
11. The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
Namasivayam V; Vanangamudi M; Kramer VG; Kurup S; Zhan P; Liu X; Kongsted J; Byrareddy SN
J Med Chem; 2019 May; 62(10):4851-4883. PubMed ID: 30516990
[TBL] [Abstract][Full Text] [Related]
12. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
13. Per-residue energy decomposition pharmacophore model to enhance virtual screening in drug discovery: a study for identification of reverse transcriptase inhibitors as potential anti-HIV agents.
Cele FN; Ramesh M; Soliman ME
Drug Des Devel Ther; 2016; 10():1365-77. PubMed ID: 27114700
[TBL] [Abstract][Full Text] [Related]
14. Revolutionizing antiretroviral therapy for human immunodeficiency virus/AIDS: A computational approach using molecular docking, virtual screening, and 3D pharmacophore building to address therapeutic failure and propose highly effective candidates.
Annan A; Raiss N; Elmir EH; Filali-Maltouf A; Medraoui L; Oumzil H
Int J Immunopathol Pharmacol; 2023; 37():3946320231207514. PubMed ID: 37850462
[TBL] [Abstract][Full Text] [Related]
15. Proposal of pharmacophore model for HIV reverse transcriptase inhibitors: Combined mutational effect analysis, molecular dynamics, molecular docking and pharmacophore modeling study.
Annan A; Raiss N; Lemrabet S; Elomari N; Elmir EH; Filali-Maltouf A; Medraoui L; Oumzil H
Int J Immunopathol Pharmacol; 2024; 38():3946320241231465. PubMed ID: 38296818
[TBL] [Abstract][Full Text] [Related]
16. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment.
Wang Y; De Clercq E; Li G
Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):813-829. PubMed ID: 31556749
[No Abstract] [Full Text] [Related]
18. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission.
D'Cruz OJ; Uckun FM
Curr HIV Res; 2006 Jul; 4(3):329-45. PubMed ID: 16842085
[TBL] [Abstract][Full Text] [Related]
19. Chemical structure and correlation analysis of HIV-1 NNRT and NRT inhibitors and database-curated, published inhibition constants with chemical structure in diverse datasets.
Viira B; García-Sosa AT; Maran U
J Mol Graph Model; 2017 Sep; 76():205-223. PubMed ID: 28738270
[TBL] [Abstract][Full Text] [Related]
20. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Farmaco; 1999; 54(1-2):26-45. PubMed ID: 10321027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
